Abstract
Application of virus therapy to treat human neoplasms has over a three decade history. MTH-68/H, a live attenuated oncolytic viral strain of the Newcastle disease virus, is one of the viruses used in the treatment of different malignancies. Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year. Four cases of advanced high-grade glioma were treated with MTH-68/H after the conventional modalities of anti-neoplastic therapies had failed. This treatment resulted in survival rates of 5–9 years, with each patient still living today. Against all odds, each patient resumed a lifestyle that resembles their previous daily routines and enjoys a good quality of life. Each of these patients has regularly received MTH-68/H as their sole form of onco-therapy for a number of years now without interruption.
Similar content being viewed by others
References
Simons JW: The Nemunaitis article reviewed: live viruses in cancer treatment. Oncology 16: 1496–1497, 2002
Bodey B, Bodey B Jr, Siegel SE: Immunophenotypical (IP) differential diagnosis and immunobiology of childhood primary brain tumors. A decade of experience. J Pediatric Hematol Oncol 6: 65–84, 1998
von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328–338, 1995
Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC: Histopathology, classification, and grading of gliomas. Glia 15: 211–221, 1995
Katsura S, Susuki J, Wada T: Statistical study of brain tumours in the neurosurgical clinics in Japan. J Neurosurg 16: 570–580, 1959
Cairncross JG: The biology of astrocytoma: lessons learned from chronic myelogenous leukemia-hypothesis. J Neuro-Oncol 5: 99–104, 1987
Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079–1087, 1990
Bullard DE, Gillespie Y, Mahaley MS, Bigner DD: Immunobiology of human gliomas. Semin Oncol 13: 94–109, 1986
Ohgaki K, Schäuble B, zur Hausen A, von Ammon K, Kleihues P: Genetic alterations associated with the evolution and progression of astrocytic brain tumors. Virchow Arch 427: 113–118, 1995
Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in tumor progression. Anticancer Res 17: 1187–1194, 1997
von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19–26, 1993
Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplifi-cation and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180–185, 1997
Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217–223, 1996
Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H: Role of gemistocytes in astrocytoma progression. Lab Invest 76: 277–284, 1997
Pollack IF, Campbell JW, Hamilton RL, Martinez AJ, Bozik ME: Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer 79: 849–856, 1997
Webb HE, Gordon Smith CE: Viruses in the treatment of cancer. Lancet 1: 1206–1208, 1970
Driever PH, Rabkin SD (eds): Replication-Competent Viruses for Cancer Therapy. Monographs in Virology. Vol 22. Karger, Basel, 2001
Nemunaitis J: Live viruses in cancer treatment. Oncology 16: 1483–1492, 2002
Nelson NJ: Viruses and cancer. J Natl Cancer Inst 91: 1709, 1999
Cassell WA, Garrett RE: Newcastle disease virus as an antineoplastic agent. Cancer 18: 863–868, 1965
Csatary LK: Viruses in the treatment of cancer. Lancet 2: 825, 1971
Csatary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P, Bodey B, Csatary CM: Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17: 619–627, 1993
Csatary LK, Csatary E, Moss RW: Scientific interest in Newcastle disease virus is reviving. J Natl Cancer Inst 92: 493–494, 2000
Csatary LK, Moss RW, Beuth J, Türücsik B, Szeberenyi J, Bakacs T: Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 19: 635–638, 1999
Fabian Z, Töröcsik B, Csatary LK, Kiss K, Szeberenyi J: Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68/H) in PC12 rat phaeochromocytoma cells. Anticancer Res 21: 125–136, 2001
Szeberenyi J, Fabian Z, Töröcsik B, Kiss K, Csatary LK: Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells. Am J Therap 10(4): 282–288, 2003
Csatary LK, Bakacs T: Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 281: 1588–1589, 1999
Steiner HH, Herold-Mende Ch, Bonsanto M, Geletneky K, Kunze S: Zur Prognose von Hirntumoren: Epidemiologie, ¨ Uberlebenszeit und klinischer Verlauf. Versicherungsmedizin 50: 173–179, 1998
Chamberlain MC, Kormanik PA: Practical guidelines for the treatment of malignant gliomas.West J Med 168: 114–120, 1998
Puzzilli F, Ruggeri A, Mastronadi L, Di Stefano D, Lunardi D: Long-term survival in cerebral glioblastoma. Case report and critical review of the literature. Tumori 84: 69–74, 1998
Pollak L, Gur R, Walach N, Reif R, Tamir L, Schiffer J: Clinical determinants of long-term survival in patients with glioblastoma multiforme. Tumori 83: 613–617, 1997
Salvati M, Cervoni L, Artico M, Caruso R, Gagliardi FM: Long-term survival in patents with supratentorial glioblastoma. J Neuro-Oncol 36: 61–64, 1998
Yoshida T, Kawano N, Oka H, Fujii K, Nakazato Y: Clinical cure of glioblastoma – two case reports. Neurol Med Chir (Tokyo) 40: 224–229, 2000
Klein R, Molenkamp G, Sorensen N, Roggendorf W: Favorable outcome of giant cell glioblastoma in a child. Report of an 11-year survival period. Childs Nerv Syst 14: 288–291, 1998
Meyer-Puttlitz B, Hayashi Y, Wahaa A, Rollbrocker B, Boström J, Wiestler OD, Louis D N, Reifenberger G, von Deimling A: Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 151: 853–857, 1997
Roth W, Weller M: Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci 56: 481–506, 1999
Fillmore HL, VanMeter TE, Broaddus WC: Membranetype matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neuro-Oncol 53: 187–202, 2001
Hosli P, Sappino AP, de Tribolet N, Dietrich PY: Malignant glioma: should chemotherapy be overthrown by experimental treatments? Ann Oncol 9: 589–600, 1998
Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP, Fueyo J: Gene therapy for glioblastomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252: 1–12, 1999
Burton EC, Prados MD: Malignant gliomas. Curr Treat Options Oncol 1: 459–468, 2000
Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ: Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 10: 17–30, 2000
Mahaley Jr MS, Bigner DD, Dudka LF, Wilds PR, Williams DH, Bouldin TW, Whitaker JN, Bynum JM: Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic glioma cells: a pilot study. J Neurosurg 59: 201–207, 1983
Mahaley MS, Gillespie GY, Gillespie RP, Watkins PJ, Bigner DD, Wikstrand CJ, MacQueen JM, Sanfilippo F: Immunobiology of primary intracranial tumors. Part 8: serological responses to active immunization of patients with anaplastic gliomas. J Neurosurg 59: 208–216, 1983
Bodey B: Spontaneous regression of neoplasms: new possibilities for immunotherapy. Expert Opin Biol Ther 2: 459–476, 2002
Tunici P, Gianni D, Finocchiaro G: Gene therapy of glioblastomas: from suicide to homicide. Prog Brain Res 132: 711–719, 2001
Schluesener HJ, Meyermann R, Deininger M: Immune responses in glioblastoma: an avenue to effective cancer therapy or a mere epiphenomenon? CTMI 265: 259–267, 2002
Karpati G, Li H, Nalbantoglu J: Molecular therapy for glioblastoma. Curr Opin Mol Ther 1: 545–552, 1999
Lorence RM, Roberts MS, Groene WS, Rabin H: Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In: Driever PH, Rabkin SD (eds): Replication-Competent Viruses for Cancer Therapy. Monographs in Virology, Vol 22. Doerr HW, Karger, 2001, 160–182
Reichard KW, Lorence RM, Cascino CJ: Selective replication of Newcastle disease virus (NDV) in cancer cells is associated with virus-induced cell fusion. Proc Am Assoc Cancer Res 33: 521, 1992
Pennisi E: Training viruses to attack cancers. Science 282: 1244–1246, 1998
Nelson NJ: Scientific interest in Newcastle disease virus is reviving. Viruses and cancer. J Natl Cancer Inst 91: 1708–1710, 1999
Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA: Newcastle disease virus selectively kills human tumor cells. J Surg Res 52: 448–453, 1992
von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19–26, 1993
Watanabe K, Tachinaba O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217–224, 1996
Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplifi-cation and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropath Exp Neurol 56: 180–185, 1997
Fazakerley J, Allsopp TE: Programmed cell death in virus infections of the nervous system. In: Gosztonyi G (ed) The Mechanisms of Neuronal Damage in Virus Infections of the Nervous System. CTMI 253: 95–119 (2001)
Fueyo J, Alemany R, Gomez-Marzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, AlfredYung WK, Lang FF: Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Ntl Cancer Inst 95: 652–660, 2003
Reichard KW, Lorence RM, Katubig BB, Peeples ME, Reyes HM: Retinoic acid enhances killing of neuroblastoma cells by Newcastle disease virus. J Pediatr Surg 28: 1221–1225, 1993
Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, Walter RJ, Peeples ME: Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 54: 6017–6021, 1994
Lam KM: Apoptosis is chicken embryo fibroblasts caused by Newcastle disease virus. Vet Microbiol 47: 357–363, 1995
Lam KM, Vasconcelos AC, Bickford AA: Apoptosis as a cause of death in chicken embryos inoculated with Newcastle disease virus. Microb Pathol 19: 169–174, 1995
Reichard KW, Lorence RM, Cascino CJ: Selective replication of Newcastle disease virus (NDV) in cancer cells is associated with virus-induced cell fusion. Proc Am Assoc Cancer Res 33: 521, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Csatary, L., Gosztonyi, G., Szeberenyi, J. et al. MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas. J Neurooncol 67, 83–93 (2004). https://doi.org/10.1023/B:NEON.0000021735.85511.05
Issue Date:
DOI: https://doi.org/10.1023/B:NEON.0000021735.85511.05